Drug Profile
Tumour-cell-vaccine-GVAX - Chinook Therapeutics
Alternative Names: CG-1940/CG-8711; CG-8123; GVAX Leukemia; GVAX Pancreas; GVAX Prostate; PANC 10.05 pcDNA-1/GM-Neo vaccine; PANC 6.03 pcDNA-1/GM-Neo vaccineLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Cell Genesys
- Developer Aduro BioTech; ANI Pharmaceuticals; BioSante Pharmaceuticals; Bristol-Myers Squibb; Cell Genesys; Chinook Therapeutics; Dana-Farber Cancer Institute; Eli Lilly and Company; Hussman Foundation; Merck Sharp & Dohme; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Class Cancer vaccines; Gene therapies; Tumour cell vaccines
- Mechanism of Action Gene transference; Granulocyte-macrophage colony-stimulating factor expression stimulants; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Acute myeloid leukaemia; Colorectal cancer; Myelodysplastic syndromes; Pancreatic cancer
- Phase I/II Prostate cancer
- No development reported Breast cancer; Cancer; Chronic myeloid leukaemia; Malignant melanoma; Multiple myeloma
- Discontinued Non-small cell lung cancer; Renal cancer
Most Recent Events
- 11 Aug 2023 Chinook Therapeutics has been acquired by Novartis
- 02 Jun 2023 Efficacy and adverse events data from a phase II trial in Pancreatic cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
- 14 Apr 2023 Efficacy data from a phase II trial in Pancreatic cancer presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)